Citius Oncology supports TenX Keane Acquisition with $67K to Extend Deal Deadline
Acquiring Company
Citius Oncology
Acquired Company
TenX Keane Acquisition
United StatesBiotechnologyHealth CareMedicalTherapeuticsPharmaceuticalBiopharmaDescription
Citius Oncology, a subsidiary of Citius Pharma, has provided $66,667 to TenX Keane Acquisition, extending their deal deadline to June 18. The agreement also includes terms for the target to receive 67.55 million shares and retain 90% ownership, with Citius Pharma contributing $10 million in cash and assuming 12.75 million existing options. At closing, remaining cash in the TenX trust account and Citius Pharma's cash will support ongoing operations and planned commercialization efforts of Citius Oncology.
Fundz sees it the moment Citius Oncology makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired TenX Keane Acquisition?
TenX Keane Acquisition was acquired by Citius Oncology, based in United States. The deal was reported on May 22, 2024. Citius Oncology, Inc. is a Delaware-based clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of cancer. Citius Oncology is publicly traded (CTOR) and operates in Biotechnology.
When did Citius Oncology acquire TenX Keane Acquisition?
Citius Oncology's acquisition of TenX Keane Acquisition was reported on May 22, 2024. Citius Oncology, a subsidiary of Citius Pharma, has provided $66,667 to TenX Keane Acquisition, extending their deal deadline to June 18. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does TenX Keane Acquisition do?
TenX Keane is a company that merged with Citius Pharmaceuticals, Inc. to form publicly listed Citius Oncology, Inc. on Nasdaq under ticker CTOR. It is privately held.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.